Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.